Management of INR 3.5 on Warfarin 6 mg Nightly
For a patient with INR 3.5 (target 2.0-3.0) on warfarin 6 mg nightly without bleeding, simply reduce the warfarin dose and recheck the INR within 1-2 weeks—no vitamin K is needed.
Immediate Management
Since your patient's INR is only modestly elevated at 3.5 and presumably has no active bleeding, the approach is straightforward per American College of Chest Physicians guidelines 1:
- Reduce the current warfarin dose (do not skip doses entirely)
- Recheck INR in 1-2 weeks
- No vitamin K administration is indicated at this level
The guidelines are clear that for INR values above therapeutic range but ≤5 without clinically significant bleeding, dose reduction alone is sufficient 1.
Dose Adjustment Strategy
Reduce the weekly warfarin dose by approximately 10-15%:
- Current dose: 6 mg daily = 42 mg/week
- Reduce by 10-15%: New weekly dose should be 36-38 mg/week
- Practical adjustment: 5.5 mg daily (38.5 mg/week, representing an 8% reduction)
This modest reduction aligns with evidence showing that the difference between INR 2.0-3.0 and 3.0-4.5 typically requires only about 1 mg/day dose adjustment 1. Since your patient is at 3.5, a smaller adjustment of 0.5 mg daily is appropriate.
Why Not Vitamin K?
Vitamin K is not recommended for INR 3.5 because 1:
- Vitamin K is reserved for INR ≥5 without bleeding, or any INR with active bleeding
- At INR 3.2-3.4, studies show that simply continuing the same dose (watchful waiting) is safe with only 1 bleeding event per 103 patients over 30 days 2
- Your patient at 3.5 is only marginally higher and dose reduction is more appropriate than vitamin K
Evidence Supporting Dose Reduction vs. Watchful Waiting
While recent research suggests that for INR values of 3.2-3.4, watchful waiting (no dose change) may be acceptable 3, 2, 4, your patient's INR of 3.5 warrants dose reduction because:
- The 2012 ACCP guidelines 5 recommend dose adjustment for single out-of-range INRs >0.5 above therapeutic
- INR 3.5 exceeds the 3.4 threshold where watchful waiting has been studied 2
- The bleeding risk increases progressively above INR 3.0 1
Follow-up Monitoring
Recheck INR in 1-2 weeks 1, 5:
- If INR returns to 2.0-3.0: Continue the reduced dose (5.5 mg daily)
- If INR remains >3.0: Make an additional 5-10% dose reduction
- If INR drops <2.0: Increase dose back slightly (to 5.75 mg daily)
Once stable, you can gradually extend monitoring intervals up to 4-6 weeks for patients with consistently therapeutic INRs 5.
Important Caveats
Assess for causes of INR elevation:
- Recent dietary changes (decreased vitamin K intake)
- New medications causing drug interactions
- Acute illness affecting warfarin metabolism
- Non-adherence followed by catch-up dosing
Consider patient-specific bleeding risk factors 1:
- Age ≥65 years (especially ≥75)
- History of stroke or GI bleeding
- Renal insufficiency or anemia
- Concurrent antiplatelet agents or NSAIDs
If your patient has multiple bleeding risk factors, you might consider a slightly larger dose reduction (15-20% instead of 10%) to achieve faster INR normalization.
Avoid excessive dose reductions (>20%) as these can cause the INR to drop too low, increasing thrombotic risk 2, 6.